RhumbLine Advisers
ARLZ

RhumbLine Advisers’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

RhumbLine Advisers’s Portfolio ARLZ Stock Details ARLZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-44,973
Closed -$160K – 3124
2016
Q1 		$160K Buy
+44,973
New +$232K ﹤0.01% 2807

Other funds holding ARLZ

PCM
PAR Capital Management Boston, Massachusetts $3.45B AUM 28.5% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return
TLCM
Tiger Legatus Capital Management New York $62.4M AUM 24.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

RhumbLine Advisers's ARLZ Position: Q2 2016 in Review

RhumbLine Advisers sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q2 2016, closing a stake of 44,973 shares — an estimated $160K sold.

RhumbLine Advisers first reported a position in ARLZ in Q1 2016 and held it in 1 quarter. The position peaked at $160K in Q1 2016. 95 funds tracked by Wall St. Rank hold ARLZ as of Q2 2016.

  • RhumbLine Advisers reported no remaining Aralez Pharmaceuticals Inc. position as of Q2 2016 after selling out during the quarter.
  • RhumbLine Advisers sold 44,973 Aralez Pharmaceuticals Inc. shares in Q2 2016, an estimated $160K.
  • RhumbLine Advisers first reported a position in Aralez Pharmaceuticals Inc. in Q1 2016 and held it in 1 quarter.
  • RhumbLine Advisers's Aralez Pharmaceuticals Inc. position peaked at $160K in Q1 2016.
  • 95 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q2 2016.

Based on RhumbLine Advisers's 13F filing for Q2 2016, filed 11 Aug 2016.